![AddexTherapeutics_logo AddexTherapeutics_logo](https://bioalps.org/app/uploads/2018/08/AddexTherapeutics_logo-e1626763863277.png)
ADDEX THERAPEUTICS Sucessfully Raises CHF40 million in Capital Increase
![](https://bioalps.org/app/uploads/2018/07/icon-line-bicolor.png)
03.04.2018
Share this article
“This is a transformational event for Addex which will enable us to advance our portfolio of allosteric modulator drug candidates through important value inflection points, including completing Phase 3 registration studies for dipraglurant,” said Tim Dyer, CEO of Addex